Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Surgery Partners (SGRY) EBIAT (2016 - 2025)

Surgery Partners (SGRY) has disclosed EBIAT for 12 consecutive years, with $161.8 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 249.12% to $161.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $183.7 million through Dec 2025, up 309.94% year-over-year, with the annual reading at $98.9 million for FY2025, 158.83% up from the prior year.
  • EBIAT hit $161.8 million in Q4 2025 for Surgery Partners, up from -$22.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $161.8 million in Q4 2025 to a low of -$118.3 million in Q4 2022.
  • Historically, EBIAT has averaged $8.1 million across 5 years, with a median of $450000.0 in 2023.
  • Biggest five-year swings in EBIAT: skyrocketed 2472.73% in 2021 and later plummeted 10750.0% in 2024.
  • Year by year, EBIAT stood at $141.5 million in 2021, then plummeted by 183.6% to -$118.3 million in 2022, then skyrocketed by 99.15% to -$1.0 million in 2023, then tumbled by 10750.0% to -$108.5 million in 2024, then surged by 249.12% to $161.8 million in 2025.
  • Business Quant data shows EBIAT for SGRY at $161.8 million in Q4 2025, -$22.7 million in Q3 2025, and $44.9 million in Q2 2025.